Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapyReport as inadecuate




Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy - Download this document for free, or read online. Document in PDF available to download.

Radiation Oncology

, 9:41

Cancer imaging and new preclinical diagnostics in radiation oncologyClinical Radiation Oncology

Abstract

BackgroundThis retrospective study aims to assess the usefulness of SUVmax from FDG-PET imaging as a prognosticator for primary biopsy-proven stage I NSCLC treated with SBRT.

MethodsThis study includes 95 patients of median age 77 years, with primary, biopsy-confirmed peripheral stage IA-IB NSCLC. All patients were treated with 60Gy in 3 fractions with a median treatment time of six days. Local, regional, and distant failures were evaluated independently according to the terms of RTOG1021. Local, regional, and distant control, overall- and progression-free survival were estimated by the Kaplan-Meier method. Cox proportional hazards regression was performed to determine whether SUVmax, age, KPS, gender, tumor size-T stage, or smoking history influenced outcomes. SUVmax was evaluated as both a continuous and as a dichotomous variable using a cutoff of <5 and ≥5.

ResultsMedian follow-up for the cohort was 16 months. Median OS and PFS were 25.3 and 40.3 months, respectively. SUV with a cutoff value of 5 predicted for OS and PFS p = .024 for each but did not achieve significance for LC p = .256. On Cox univariate regression analysis, SUV as a dichotomous variable predicted for both OS and PFS p = .027 and p = .030, respectively. Defined as a continuous variable, SUVmax continued to predict for OS and PFS p = .032 and p = .003, but also predicted LC p = .045 and trended toward significance for DC p = .059.

SUVmax did not predict for OS as a dichotomous or continuous variable. It did, however, predict for PFS as a continuous variable p = .008, neared significance for local control p = .057 and trended towards, significance for distant control p = .092.

ConclusionsSUVmax appears to be a statistically and clinically significant independent prognostic marker for progression-free survival in patients with stage I NSCLC treated with SBRT. Prospective studies to more accurately define the role of tumor FDG uptake in the prognosis of NSCLC are warranted.

Electronic supplementary materialThe online version of this article doi:10.1186-1748-717X-9-41 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Zachary D Horne - David A Clump - John A Vargo - Samir Shah - Sushil Beriwal - Steven A Burton - Annette E Quinn - Mat

Source: https://link.springer.com/







Related documents